Latest News

Amit Gupta, MBBS, DNB, joins the show to discuss diabetes treatment in a traditionally underserved population and to address the IDF’s work in moving it forward.

Eli Lilly announced FDA approval of a 250 mg every-8-week lebrikizumab maintenance regimen, supported by 32-week ADjoin extension data.

Sparrow Pharmaceuticals presented phase 2a data for the HSD-1 inhibitor clofutriben at ADA 2026.

The FDA marked bemotrizinol as first new active ingredient on the over-the-counter (OTC) sunscreen monograph since the 1990s.

Learn what the first-ever CKM syndrome guideline means for screening, treatment, and the connection between heart disease, kidney disease, diabetes, and obesity.

Elecoglipron 75 mg produced 10.5% body weight reduction at 26 weeks in VISTA and a 1.9% HbA1c reduction at 26 weeks in SOLSTICE.

At ATS 2026, Robert Wallis, MD, discussed PanTB-HM findings on FEV1 recovery and NAC antimicrobial interactions.

Ketan Dhatariya, MD, PhD, MS, joins the show to discuss how therapies for diabetes have evolved in the UK in comparison to the US.

twiist improved time in range by 16 percentage points and reduced HbA1c by 0.7 points over 13 weeks in insulin-treated adults with type 2 diabetes, with no severe hypoglycemia events.

In the phase 2 SLIMMER-UP-SWITCH trial, ecnoglutide delivered greater weight loss and waist circumference reduction than semaglutide at 20 weeks in adults with obesity in China.

Trang Ly, PhD, MBBS, joins the show to discuss Insulet’s recent advancements in automated insulin delivery and the trajectory of the Omnipod platform.

DKA remains a growing challenge in diabetes care, with new data highlighting missed diagnoses, rising admissions, and higher costs.

Stay updated with the latest healthcare breakthroughs, including FDA regulatory decisions, phase 3 data, and new clinical guidelines.

A new substudy of VESALIUS-CV presented at ADA 2026 has confirmed that evolocumab’s cardioprotective effects extend to patients at risk from diabetes.

Across a trio of phase 3 trials, CagriSema delivered superior HbA1c reduction and weight loss versus semaglutide in adults with type 2 diabetes

Orforglipron added to titrated insulin glargine reduced HbA1c by up to 2.05% and body weight by up to 6.1% versus placebo, without increasing hypoglycemia risk.

In a post-hoc analysis of ATTAIN-1 and ATTAIN-2, the highest dose of orforglipron delivered meaningful weight loss across all menopause stages.

May 2026 spotlights the ATS 2026 conference and the ALA's State of the Air report.

Eugene Wright, Jr., MD, joins the show to discuss the current state of technological integration into diabetes care, from glucose monitors to insulin delivery and beyond.

Eli Lilly’s investigative GLP-1/GIP/glucagon triple agonist has demonstrated its efficacy in reducing several major factors of obesity versus placebo.

Eli Lilly’s investigative GLP-1/GIP/glucagon triple agonist has outperformed placebo in patients with poorly-controlled T2D.

The CONNECT trial found CGM improved A1C and time in range in adults with type 2 diabetes not on insulin.

A post-hoc analysis of the STEP UP trial found that semaglutide 7.2 mg and 2.4 mg were linked to eGFR increases in adults with obesity who did not have diabetes.